266 related articles for article (PubMed ID: 21543472)
21. Immune reconstitution inflammatory syndrome in a patient with progressive multifocal leukoencephalopathy.
Shahani L; Shah M; Tavakoli-Tabasi S
BMJ Case Rep; 2015 Jun; 2015():. PubMed ID: 26063110
[TBL] [Abstract][Full Text] [Related]
22. Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome (IRIS).
Bauer J; Gold R; Adams O; Lassmann H
Acta Neuropathol; 2015 Dec; 130(6):751-64. PubMed ID: 26323992
[TBL] [Abstract][Full Text] [Related]
23. BKV and JCV large T antigen-specific CD8+ T cell response in HLA A*0201+ kidney transplant recipients with polyomavirus nephropathy and patients with progressive multifocal leukoencephalopathy.
Chen Y; Trofe J; Gordon J; Autissier P; Woodle ES; Koralnik IJ
J Clin Virol; 2008 Jun; 42(2):198-202. PubMed ID: 18295538
[TBL] [Abstract][Full Text] [Related]
24. Immune reconstitution is not a prognostic factor in progressive multifocal leukoencephalopathy.
Harrison DM; Newsome SD; Skolasky RL; McArthur JC; Nath A
J Neuroimmunol; 2011 Sep; 238(1-2):81-6. PubMed ID: 21840066
[TBL] [Abstract][Full Text] [Related]
25. Progressive multifocal leukoencephalopathy: new concepts.
Lima MA
Arq Neuropsiquiatr; 2013 Sep; 71(9B):699-702. PubMed ID: 24141508
[TBL] [Abstract][Full Text] [Related]
26. Brief Report: Role of Thymic Reconstitution in the Outcome of AIDS-Related PML.
Chalkias SG; Gheuens S; Bord E; Batson S; Koralnik IJ
J Acquir Immune Defic Syndr; 2015 Dec; 70(4):357-61. PubMed ID: 26181821
[TBL] [Abstract][Full Text] [Related]
27. Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy.
Cortese I; Muranski P; Enose-Akahata Y; Ha SK; Smith B; Monaco M; Ryschkewitsch C; Major EO; Ohayon J; Schindler MK; Beck E; Reoma LB; Jacobson S; Reich DS; Nath A
N Engl J Med; 2019 Apr; 380(17):1597-1605. PubMed ID: 30969503
[TBL] [Abstract][Full Text] [Related]
28. Progressive multifocal leukoencephalopathy.
Weissert R
J Neuroimmunol; 2011 Feb; 231(1-2):73-7. PubMed ID: 20937530
[TBL] [Abstract][Full Text] [Related]
29. Incidence and prognosis of immune reconstitution inflammatory syndrome in HIV-associated progressive multifocal leucoencephalopathy.
Sainz-de-la-Maza S; Casado JL; Pérez-Elías MJ; Moreno A; Quereda C; Moreno S; Corral I
Eur J Neurol; 2016 May; 23(5):919-25. PubMed ID: 26914970
[TBL] [Abstract][Full Text] [Related]
30. Cellular and humoral immune response in progressive multifocal leukoencephalopathy.
Weber F; Goldmann C; Krämer M; Kaup FJ; Pickhardt M; Young P; Petry H; Weber T; Lüke W
Ann Neurol; 2001 May; 49(5):636-42. PubMed ID: 11357954
[TBL] [Abstract][Full Text] [Related]
31. TCR bias and HLA cross-restriction are strategies of human brain-infiltrating JC virus-specific CD4+ T cells during viral infection.
Yousef S; Planas R; Chakroun K; Hoffmeister-Ullerich S; Binder TM; Eiermann TH; Martin R; Sospedra M
J Immunol; 2012 Oct; 189(7):3618-30. PubMed ID: 22942431
[TBL] [Abstract][Full Text] [Related]
32. Brief Report: Decreased JC Virus-Specific Antibody-Dependent Cellular Cytotoxicity in HIV-Seropositive PML Survivors.
Tan CS; Ghofrani J; Geiger E; Koralnik IJ; Jost S
J Acquir Immune Defic Syndr; 2019 Oct; 82(2):220-224. PubMed ID: 31513076
[TBL] [Abstract][Full Text] [Related]
33. T cell deficiencies as a common risk factor for drug associated progressive multifocal leukoencephalopathy.
Pavlovic D; Patel MA; Patera AC; Peterson I;
Immunobiology; 2018; 223(6-7):508-517. PubMed ID: 29472141
[TBL] [Abstract][Full Text] [Related]
34. Low frequency of cytotoxic T lymphocytes against the novel HLA-A*0201-restricted JC virus epitope VP1(p36) in patients with proven or possible progressive multifocal leukoencephalopathy.
Du Pasquier RA; Kuroda MJ; Schmitz JE; Zheng Y; Martin K; Peyerl FW; Lifton M; Gorgone D; Autissier P; Letvin NL; Koralnik IJ
J Virol; 2003 Nov; 77(22):11918-26. PubMed ID: 14581528
[TBL] [Abstract][Full Text] [Related]
35. Severe Progressive Multifocal Leukoencephalopathy (PML) and Spontaneous Immune Reconstitution Inflammatory Syndrome (IRIS) in an Immunocompetent Patient.
Krey L; Raab P; Sherzay R; Berding G; Stoll M; Stangel M; Wegner F
Front Immunol; 2019; 10():1188. PubMed ID: 31191548
[No Abstract] [Full Text] [Related]
36. Pathology for severe inflammatory PML with PD1/PD-L1 expression of favorable prognosis: What's a prognostic factor for PML-IRIS?
Shishido-Hara Y; Akimoto J; Fukami S; Kohno M; Matsubayashi J; Nagao T
Neuropathology; 2024 Feb; 44(1):47-58. PubMed ID: 37424276
[TBL] [Abstract][Full Text] [Related]
37. Immunology of progressive multifocal leukoencephalopathy.
Jelcic I; Jelcic I; Faigle W; Sospedra M; Martin R
J Neurovirol; 2015 Dec; 21(6):614-22. PubMed ID: 25740538
[TBL] [Abstract][Full Text] [Related]
38. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study.
Jilek S; Jaquiéry E; Hirsch HH; Lysandropoulos A; Canales M; Guignard L; Schluep M; Pantaleo G; Du Pasquier RA
Lancet Neurol; 2010 Mar; 9(3):264-72. PubMed ID: 20117055
[TBL] [Abstract][Full Text] [Related]
39. Inadequate Immune Humoral Response against JC Virus in Progressive Multifocal Leukoencephalopathy Non-Survivors.
Solis M; Guffroy A; Lersy F; Soulier E; Gallais F; Renaud M; Douiri N; Argemi X; Hansmann Y; De Sèze J; Kremer S; Fafi-Kremer S
Viruses; 2020 Dec; 12(12):. PubMed ID: 33276614
[TBL] [Abstract][Full Text] [Related]
40. Clinical outcome of long-term survivors of progressive multifocal leukoencephalopathy.
Lima MA; Bernal-Cano F; Clifford DB; Gandhi RT; Koralnik IJ
J Neurol Neurosurg Psychiatry; 2010 Nov; 81(11):1288-91. PubMed ID: 20710013
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
